Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride Following Intravenous Infusion of [14C] Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy.

Trial Profile

Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride Following Intravenous Infusion of [14C] Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2012

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Cancer; Haematological malignancies
  • Focus Pharmacokinetics
  • Sponsors Cephalon
  • Most Recent Events

    • 14 Feb 2012 Official title amended as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top